Table 1. Clinical and Serological Background of Subjects.
| NAFLD | ||||||
|---|---|---|---|---|---|---|
| Stage 0-1 (n = 33) | Stage 2 (n = 29) | Stage 3 (n = 29) | Stage 4 (n = 20) | HCC without LC (n = 13) | HCC with LC (n = 10) | |
| Male/Female | 16/17 | 12/17 | 8/21 | 6/14 | 10/3 | 7/3 |
| Age (year) | 55 (25–78) | 60 (19–81) | 64 (31–83) | 68 (20–51) | 74.3 (56–91) | 74.6 (66–82) |
| BMI (kg/m2) | 28.8 (22.2–38.5) | 27.1 (20.8–37.4) | 28.0 (24.7–34.9) | 28.0 (20.1–36.9) | 24.6 (18.3–31.29) | 23.7 (20.9–26.6) |
| Platelet (x104/mm3) | 20.5 (7.8–30) | 20.6 (10.4–40.5) | 19.7 (9.5–30.5) | 9.6 (3.9–25.1) | 16.5 (7.9–24.8) | 12.4 (2.9–27.1) |
| Albumin (g/dL) | 4.3 (3.2–5.3) | 4.4 (3.6–5.4) | 4.3 (3.4–4.9) | 4.0 (2.6–4.7) | 3.9 (3.3–4.8) | 3.9 (2.9–4.5) |
| Total bilirubin (mg/dl) | 0.7 (0.3–2.6) | 0.8 (0.3–2.4) | 1.0 (0.4–2.4) | 1.2 (0.3–2.5) | 1.2 (0.6–1.3) | 0.9 (0.5–3.9) |
| AST (IU/U) | 40 (15–147) | 43 (17–245) | 67 (26–186) | 53 (26–120) | 59 (17–256) | 48 (21–84) |
| ALT (IU/L) | 77 (14–277) | 74 (12–29) | 71 (32–318) | 42 (10–138) | 43 (15–114) | 44 (13–69) |
| Type IV collagen 7s (ng/ml) | 3.9 (2.7–7.1) | 5.0 (2.5–9.3) | 6.2 (3.8–8.9) | 7.8 (5.8–9.6) | 7.0 (5.0–9.0) | 9.9 (7.0–14.0) |
| Hyaluronic acid (ng/ml) | 27 (10–33) | 43 (12–751) | 65 (12–267) | 167 (29–451) | 144 (25–218) | 386 (70–1380) |
| WFA+-M2BP (COI) | 0.80 (0.24–3.87) | 0.74 (0.3–2.32) | 0.84 (0.3–5.08) | 1.95 (1.13–11.2) | ||
| APRI | 0.53 (0.23–2.36) | 0.67 (0.25–2.86) | 1.19 (0.33–3.41) | 1.53 (0.45–3.57) | 1.00 (0.18–2.58) | 1.73 (0.51–4.14) |
| FIB-4 index | 1.27 (0.46–5.64) | 1.40 (0.55–4.98) | 2.76 (0.70–6.83) | 5.12 (1.27–15.89) | 4.00 (1.52–11.09) | 7.17 (2.63–15.04) |
| AFP (ng/ml) | 196 (2.1–1241) | 4.6 (0.9–8.1) | ||||
| PIVKA-II (mAU/ml) | 4367 (18–22448) | 369.8 (10–3205) | ||||
Data are presented as the median (range).
BMI, body mass index; APRI, AST-to-platelet ratio index.